Baylisascariasis

Summary

Baylisascariasis (MONDO:0000297) is a disease. A subtype of Ascaridida infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	baylisascariasis
Mondo ID	MONDO:0000297
DOID	DOID:0050259
NCIT	C128397
UMLS	C0277150
MedGen	547881
GARD	0012654
Is cancer (heuristic)	no

Also known as: Baylisascaris procyonis caused disease or disorder · Baylisascaris procyonis disease or disorder · Baylisascaris procyonis infectious disease · raccoon roundworm infection

Disease family

This is a subtype of Ascaridida infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › Nematoda infectious disease › Rhabditida infectious disease › Ascaridida infectious disease › baylisascariasis

Related subtypes (5): ascariasis, ascaridiasis, toxascariasis, toxocariasis, anisakiasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.